Myoclonic astatic epilepsy and the use of the ketogenic diet

Epilepsy Research

Volumn 100, Issue 3, 2012, Pages 258-260

  Bergqvist, A G Christina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ketogenic diet; Myoclonic astatic epilepsy; Treatments

Indexed keywords

CARBAMAZEPINE; CORTICOTROPIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; OXCARBAZEPINE; PREDNISONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGE DISTRIBUTION; ARTICLE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; ELECTROENCEPHALOGRAM; GENERALIZED EPILEPSY; HUMAN; INCIDENCE; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; MEDICAL INFORMATION; MYOCLONIC ASTATIC EPILEPSY; PATHOGENESIS; PRIORITY JOURNAL; RARE DISEASE; SEX RATIO; TREATMENT OUTCOME;

AGE OF ONSET; ANIMALS; EPILEPSIES, MYOCLONIC; EPILEPSY, GENERALIZED; HUMANS; KETOGENIC DIET; SEIZURES;

EID: 84864077253     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.04.009     Document Type: Article

References (24)

1. Bergqvist A.G., Schall J.I., Gallagher P.R., Cnaan A., Stallings V.A. Fasting versus gradual initiation of the ketogenic diet: a prospective, randomized clinical trial of efficacy. Epilepsia 2005, 46:1810-1819.
2. Caraballo R.H., Cersosimo R.O., Sakr D., Cresta A., Escobal N., Fejerman N. Ketogenic diet in patients with myoclonic-astatic epilepsy. Epileptic Disord. 2006, 8:151-155.
3. Doose H. Myoclonic-astatic epilepsy. Epilepsy Res. 1992, (Suppl. 6):163-168.
4. Doose H., Gerken H., Leonhardt R., Volzke E., Volz C. Centrencephalic myoclonic-astatic petit mal. Clinical and genetic investigation. Neuropadiatrie 1970, 2:59-78.
5. Fejerman N., Caraballo R., Cersosimo R. Ketogenic diet in patients with Dravet syndrome and myoclonic epilepsies in infancy and early childhood. Adv. Neurol. 2005, 95:299-305.
6. Guerrini R., Aicardi J. Epileptic encephalopathies with myoclonic seizures in infants and children (severe myoclonic epilepsy and myoclonic-astatic epilepsy). J. Clin. Neurophysiol. 2003, 20:449-461.
7. Henderson C.B., Filloux F.M., Alder S.C., Lyon J.L., Caplin D.A. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J. Child Neurol. 2006, 21:193-198.
8. Ito M., Ohmori I., Nakahori T., Ouchida M., Ohtsuka Y. Mutation screen of GABRA1, GABRB2 and GABRG2 genes in Japanese patients with absence seizures. Neurosci. Lett. 2005, 383:220-224.
9. Kilaru S., Bergqvist A.G. Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia. Epilepsia 2007, 48:1703-1707.
10. Kim D.W., Kang H.C., Park J.C., Kim H.D. Benefits of the nonfasting ketogenic diet compared with the initial fasting ketogenic diet. Pediatrics 2004, 114:1627-1630.
11. Kossoff E., Bosarge J., Miranda M., Wiemer-Kruel A., Kang H., Kim H. Will seizure control improve by switching from the modified Atkins diet to the traditional ketogenic diet. Epilepsia 2010, 51:2496-2499.
12. Kossoff E.H., Dorward J.L. The modified Atkins diet. Epilepsia 2008, 49(Suppl. 8):37-41.
13. Nabbout R., Dulac O. Epileptic syndromes in infancy and childhood. Curr. Opin. Neurol. 2008, 21:161-166.
14. Nabbout R., Kozlovski A., Gennaro E., Bahi-Buisson N., Zara F., Chiron C., Bianchi A., Brice A., Leguern E., Dulac O. Absence of mutations in major GEFS+ genes in myoclonic astatic epilepsy. Epilepsy Res. 2003, 56:127-133.
15. Neal E.G., Chaffe H., Schwartz R.H., Lawson M.S., Edwards N., Fitzsimmons G., Whitney A., Cross J.H. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008, 7:500-506.
16. Neubauer B.A., Hahn A., Doose H., Tuxhorn I. Myoclonic-astatic epilepsy of early childhood - definition, course, nosography, and genetics. Adv. Neurol. 2005, 95:147-155.
17. Oguni H., Fukuyama Y., Tanaka T., Hayashi K., Funatsuka M., Sakauchi M., Shirakawa S., Osawa M. Myoclonic-astatic epilepsy of early childhood - clinical and EEG analysis of myoclonic-astatic seizures, and discussions on the nosology of the syndrome. Brain Dev. 2001, 23:757-764.
18. Oguni H., Tanaka T., Hayashi K., Funatsuka M., Sakauchi M., Shirakawa S., Osawa M. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002, 33:122-132.
19. Rubenstein J.E., Kossoff E.H., Pyzik P.L., Vining E.P., McGrogan J.R., Freeman J.M. Experience in the use of the ketogenic diet as early therapy. J. Child Neurol. 2005, 20:31-34.
20. Scheffer I.E., Wallace R., Mulley J.C., Berkovic S.F. Clinical and molecular genetics of myoclonic-astatic epilepsy and severe myoclonic epilepsy in infancy (Dravet syndrome). Brain Dev. 2001, 23:732-735.
21. Stephani U. The natural history of myoclonic astatic epilepsy (Doose syndrome) and Lennox-Gastaut syndrome. Epilepsia 2006, 47(Suppl. 2):53-55.
22. Thomas P., Valton L., Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006, 129:1281-1292.
23. Weber P., Tillmann B., Minet J.C., Blauenstein U. Myoclonic-astatic epilepsy in early childhood: review of clinical signs, EEG features, etiology, and therapy. Klin. Padiatr. 2002, 214:279-284.
24. Zupanc M.L., Roell Werner R., Schwabe M.S., O'Connor S.E., Marcuccilli C.J., Hecox K.E., Chico M.S., Eggener K.A. Efficacy of felbamate in the treatment of intractable pediatric epilepsy. Pediatr. Neurol. 2010, 42:396-403.